---
layout: default
title: 2-Mercaptoethanol Borosilicate Glass Carbon Monoxi
parent: 僅模型預測 (L5)
nav_order: 19
evidence_level: L5
indication_count: 0
---

# 2-Mercaptoethanol Borosilicate Glass Carbon Monoxi
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Unknown Substance Mixture: Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

The submitted entry does not correspond to a single drug — it contains a semicolon-delimited list of ten unrelated chemical substances (including industrial chemicals, pesticides, solvents, and excipients). No predicted indications, no regulatory approvals, and no clinical evidence exist for this entry as a therapeutic agent. A repurposing evaluation cannot be performed until a valid, single active pharmaceutical ingredient is identified and resubmitted.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None recorded |
| Predicted New Indication | None — TxGNN returned no candidates |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only) — no predictions generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why This Entry Cannot Be Evaluated

The `inn` field submitted to the pipeline contains ten chemically unrelated substances joined by semicolons:

| # | Substance | Nature |
|---|-----------|--------|
| 1 | 2-Mercaptoethanol | Reducing agent / industrial solvent |
| 2 | Borosilicate Glass | Inert material / container |
| 3 | Carbon Monoxide | Industrial gas |
| 4 | Ethyl Butylacetylaminopropionate | Insect repellent (IR3535) |
| 5 | Hops Oil | Plant extract / flavouring |
| 6 | Liquid Petroleum | Mineral oil / excipient |
| 7 | MCPA | Herbicide (phenoxy acetic acid class) |
| 8 | Polyvinyl Alcohol, Unspecified | Polymer excipient |
| 9 | Titanium Dioxide | Pigment / coating excipient |
| 10 | Tralomethrin | Pyrethroid insecticide |

None of these is an approved pharmaceutical active ingredient in the conventional sense, and collectively they do not constitute a recognised drug combination. The TxGNN model correctly returned zero repurposing candidates because no matching DrugBank node could be resolved.

No mechanism of action analysis is possible, and no disease association is scientifically meaningful for this entry as submitted.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to individual substance safety data sheets (SDS) for each of the ten substances listed. Standard pharmaceutical safety evaluation (DDI, contraindications, clinical warnings) is not applicable because no single therapeutic agent is identified.

> **Note on individual substance hazards**: Several substances in this list carry significant non-pharmaceutical hazards — Carbon Monoxide is acutely toxic (IDLH 1,200 ppm); MCPA and Tralomethrin are registered pesticides with specific regulatory handling requirements; 2-Mercaptoethanol is a flammable, irritant reducing agent. If any of these are present in a formulation context, occupational exposure controls and SDS-based risk assessment should apply.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The submitted entry does not represent a drug candidate — it is a heterogeneous list of ten unrelated chemical substances, none of which individually maps to a DrugBank therapeutic entity. No repurposing evaluation can proceed on this basis.

**To proceed, the following is needed:**

1. **Identify the correct INN**: Determine whether this entry originated from a database parsing error (e.g., an entire formulation row was mistakenly concatenated into a single drug field).
2. **Resubmit as individual substances**: If any single component is the intended drug of interest (e.g., Tralomethrin for a repurposing hypothesis in parasitology, or Ethyl Butylacetylaminopropionate for dermatology), resubmit that component alone.
3. **Resolve upstream pipeline issue**: The semicolon-delimited multi-substance string suggests a data ingestion bug. Audit the TFDA raw data parser to ensure ingredient lists are not being collapsed into the `inn` field.
4. **Obtain DrugBank ID**: Once a valid INN is isolated, retrieve its DrugBank ID before re-running TxGNN to enable meaningful prediction scoring.
5. **Re-run the full pipeline**: After data correction, re-execute evidence collection (ClinicalTrials.gov, PubMed, DrugBank MOA) and regenerate the Evidence Pack.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

